$1.87
4.59% yesterday
Nasdaq, Apr 07, 10:17 pm CET
ISIN
US5171251003
Symbol
LRMR

Larimar Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Larimar Therapeutics Inc Classifications & Recommendation:

Buy
100%

Larimar Therapeutics Inc Price Target

Target Price $20.64
Price $1.87
Potential
Number of Estimates 11
11 Analysts have issued a price target Larimar Therapeutics Inc 2026 . The average Larimar Therapeutics Inc target price is $20.64. This is higher than the current stock price. The highest price target is
$40.00 2,039.04%
register free of charge
, the lowest is .
A rating was issued by 12 analysts: 12 Analysts recommend Larimar Therapeutics Inc to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Larimar Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Larimar Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.32 -1.90
57.14% 43.94%
P/E negative

5 Analysts have issued a Larimar Therapeutics Inc forecast for earnings per share. The average Larimar Therapeutics Inc EPS is

$-1.90
Unlock
. This is
45.04% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.52 16.03%
Unlock
, the lowest is
$-2.51 91.60%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.32 57.14%
2025
$-1.90 43.94%
Unlock
2026
$-2.29 20.53%
Unlock
2027
$-1.55 32.31%
Unlock
2028
$-0.39 74.84%
Unlock
2029
$2.59 764.10%
Unlock

P/E ratio

Current -1.43 83.82%
2025
-0.99 30.77%
Unlock
2026
-0.82 17.17%
Unlock
2027
-1.21 47.56%
Unlock
2028
-4.86 301.65%
Unlock
2029
0.72 114.81%
Unlock

Current Larimar Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Baird
Locked
Locked
Locked Mar 25 2025
Guggenheim
Locked
Locked
Locked Mar 25 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 25 2025
Truist Securities
Locked
Locked
Locked Jan 29 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 24 2025
HC Wainwright & Co.
Locked
Locked
Locked Dec 17 2024
HC Wainwright & Co.
Locked
Locked
Locked Dec 16 2024
Analyst Rating Date
Locked
Baird:
Locked
Locked
Mar 25 2025
Locked
Guggenheim:
Locked
Locked
Mar 25 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 25 2025
Locked
Truist Securities:
Locked
Locked
Jan 29 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 24 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Dec 17 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Dec 16 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today